ZYME
Zymeworks Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +11.8% ·
share flow +7.5% ·
net new positions +5.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.51M | $39.99M | n/a | n/a |
| Q2 2026 | 88 | -1 | 24.75M | $646.12M | +6 | −9 |
| Q1 2026 | 94 | +3 | 24.89M | $623.10M | +9 | −6 |
| Q4 2025 | 90 | -1 | 25.71M | $677.12M | n/a | −1 |
| Q3 2025 | 19 | +2 | 15.73M | $268.60M | +2 | −1 |
| Q2 2025 | 15 | +1 | 10.33M | $129.64M | +1 | n/a |
| Q1 2025 | 11 | 0 | 3.31M | $39.41M | +1 | −1 |
| Q4 2024 | 11 | -2 | 3.00M | $43.95M | n/a | −2 |
| Q3 2024 | 12 | +2 | 2.16M | $27.11M | +2 | n/a |
| Q2 2024 | 10 | n/a | 2.50M | $21.29M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 3.99M | +5.2% | $68.14M | 0.0% | ▲ Add | 2 | SEC ↗ ×13 |
| 2 | Morgan Stanley ✦ | 3.98M | n/a | $68.06M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 3 | The Vanguard Group ✦ (passive) | 2.15M | -12.6% | $36.80M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | Millennium Management ✦ | 1.10M | +851.6% | $18.87M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 1.08M | -0.7% | $18.47M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 678.64K | -3.8% | $11.59M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Adage Capital Partners ✦ | 564.00K | +18.5% | $9.63M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Goldman Sachs Group ✦ | 443.52K | n/a | $7.58M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 431.70K | -19.1% | $7.37M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 313.75K | New | $5.36M | 0.0% | New | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 206.86K | -16.0% | $3.53M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Wellington Management ✦ | 168.69K | -6.6% | $2.88M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 13 | Marshall Wace ✦ | 154.86K | New | $2.64M | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 152.63K | -8.1% | $2.61M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 15 | D. E. Shaw & Co. ✦ | 126.92K | -50.3% | $2.17M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 16 | Fisher Asset Management ✦ | 71.97K | 0.0% | $1.23M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | JPMorgan Chase ✦ | 67.77K | n/a | $1.16M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 18 | T. Rowe Price ✦ | 26.82K | 0.0% | $459,000 | 0.0% | Held | 6 | SEC ↗ |
| 19 | Fidelity (FMR) ✦ | 3.51K | +13.0% | $60,016 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $5.36M | 0.0% |
| Marshall Wace | $2.64M | 0.0% |
Exited
| Norges Bank | $2.53M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 209 holders, 70.12M shares, $1.75B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 13.83K sh · $357,557
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology